3:15 pm Identifying MASH Patients with Active Fibrogenesis: Biomarker Strategies for Early Proof-of-Concept Antifibrotic Trials
Time: 3:15 pm
day: Conference Day 1
Details:
- Differentiating fibrosis stage from fibrogenic activity in the context of antifibrotic therapy development
- Leveraging real-world screening data to characterize patients with active, ongoing fibrogenesis
- Exploring pre-identification tools (including but not limited to AST, FAST score and LiverPRO) and treatment monitoring strategies
